Navigation Links
New Data from Multiple Studies Show Galvus Delivers Consistent and,Robust Blood Sugar Control in Patients with Type 2 Diabetes

* Significant blood sugar reductions seen across range of patient populations, including varied ethnic groups, the elderly, and those at high risk of developing diabetes

* Galvus lowers blood sugar when added to a sulfonylurea, reinforcing efficacy in combination with commonly used diabetes medicines

* Data confirm good tolerability in humans with studies showing incidence of side effects similar to placebo in monotherapy trials

* European regulatory decision anticipated by end 2007; discussions continue on steps to gain US approval

BASEL, Switzerland, June 25, 2007 - Galvus® (vildagliptin), a new once-daily oral treatment for type 2 diabetes submitted for approval in the US and Europe, has been shown in new clinical data to deliver consistent and robust blood sugar reductions in patients with this progressive disease estimated to affect about 246 million people worldwide[1].

The findings, presented at the 67th Annual Scientific Sessions of the American Diabetes Association (ADA), are consistent with earlier results demonstrating the efficacy and tolerability of Galvus both as a monotherapy and when added to many commonly used diabetes medicines in a range of patients across the type 2 diabetes disease spectrum[2],[3],[4]. These include varied ethnic groups[3] and the elderly[4] as well as patients with impaired glucose tolerance at high risk of developing diabetes[5] and those with uncontrolled blood sugar levels[6].

"These results further reinforce the clinical benefits of Galvus as an important new treatment option for patients with type 2 diabetes," said James Shannon, MD, Global Head of Development at Novartis Pharma AG. "We remain convinced that Galvus is safe and effective and will continue to work with health authorities to ensure this medicine can be made available to patients worldwide as soon as possible."

A member of a new class of diabetes medici
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstroms Macroglobulinemia
2. Velcade (Bortezomib) for Injection Based Therapies Produced Complete Remission Rates as High as 54 Percent in Patients With Previously Treated Multiple Myeloma
3. Velcade (bortezomib) for Injection Based Therapies Achieved Survival Rates as High as 100 Percent in Newly Diagnosed Multiple Myeloma Patients
4. Gentiums Defibrotide Seen as Active in Multiple Myeloma
5. ACE-011 Improves Multiple Myeloma Bone Disease in a Preclinical Model
6. CytRx Announces Clinical Results from Its Rising Multiple Dose Trial with Arimoclomol for ALS
7. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
8. Velcade (bortezomib) for Injection Survival Data in Front-Line Multiple Myeloma Patients to be Featured at 11th International Myeloma Workshop
9. New Research Demonstrates Broad Efficacy of Azixa (MPC-6827) Against Multiple Tumor Types and in Drug Resistant Cell Lines
10. Orchestra Therapeutics Announces New Phase II Clinical Data on NeuroVax Demonstrating Marked Expansion of Regulatory T Cell Populations in Patients With Multiple Sclerosis
11. Trexima (Sumatriptan/Naproxen Sodium) Demonstrated Migraine-Free Response Across Multiple Attacks
Post Your Comments:
(Date:8/21/2008)...d EMERYVILLE, Calif., Aug. 21 /PRNewswire-FirstCal...nyx Pharmaceuticals, Inc.,(Nasdaq: ONXX ) today a...ts,in the STORM Sorafenib as Adjuvant Treatment in...rcinoma trial. The randomized, double-blind,place...R) (sorafenib),tablets as adjuvant treatment, whic...
(Date:8/20/2008)... 20 /- Enobia Pharma, an emerging bio...ics for serious bone,disorders, today announced th...ypophosphatasia has been dosed. Enobia is investig...40 for the treatment of this rare and,often crippl...proved,treatment., Under two separate protocols, ...
(Date:8/19/2008)...lia, Aug. 20 /Xinhua--,Phar...SL) today announced,that the Phase 3 clinical tria... subjects with bronchiectasis has concluded with n...llowing 12 months of treatment., A total of 123 s...wice,per day and 99 subjects completed the full 12...
(Date:8/19/2008)...nd tissue samples to be used to identify molecular...ss., Aug. 19 /PRNewswire-USNewswire/ -- ALS Therap...the acceleration of an ALS,biomarker effort using ...k,of clinical partnerships. These ongoing projects...ndentify the altered expression of genes,and prote...
Breaking Medicine Technology:Bayer and Onyx Begin Enrollment in STORM Trial Studying Nexavar as Adjuvant Therapy for Patients With Liver Cancer 2Bayer and Onyx Begin Enrollment in STORM Trial Studying Nexavar as Adjuvant Therapy for Patients With Liver Cancer 3Bayer and Onyx Begin Enrollment in STORM Trial Studying Nexavar as Adjuvant Therapy for Patients With Liver Cancer 4Bayer and Onyx Begin Enrollment in STORM Trial Studying Nexavar as Adjuvant Therapy for Patients With Liver Cancer 5Enobia Pharma Initiates Clinical Testing of Enzyme Replacement Therapy to Treat Hypophosphatasia 2Enobia Pharma Initiates Clinical Testing of Enzyme Replacement Therapy to Treat Hypophosphatasia 312 Month Phase 3 Trial Finds Bronchitol Safe in Bronchiectasis 212 Month Phase 3 Trial Finds Bronchitol Safe in Bronchiectasis 3ALS Therapy Development Institute Partners with Clinical Centers to Establish Pathological Mechanisms of Lou Gehrig's Disease 2ALS Therapy Development Institute Partners with Clinical Centers to Establish Pathological Mechanisms of Lou Gehrig's Disease 3HIV Drugs Linked to Increased Risk of Heart Attack 15747 1HIV Drugs Linked to Increased Risk of Heart Attack 15747 2HIV Drugs Linked to Increased Risk of Heart Attack 15747 3Sonic Innovations Celebrates 10 Year Anniversary 15745 1Sonic Innovations Celebrates 10 Year Anniversary 15745 2Sonic Innovations Celebrates 10 Year Anniversary 15745 3Genoptix Announces 2008 Annual Stockholders Meeting and Date of Record 15743 1AMERIGROUP Successful Bidder in DC RFP 15741 1AMERIGROUP Successful Bidder in DC RFP 15741 2
(Date:8/21/2008)... New names and fresh websit... UME/GME administration software , ... one45 Software, a leading provider of healthcare ... of Cytiva Software Inc. (CRX:TSX.V), announced to...hcare education administration products., , ,Compl...
(Date:8/20/2008)... NEWTON, Mass., Aug. 20 /PRNewswire/ -- Questex M...o-business media company and owner of,American Spa... and the,International Beauty Shows, the Internati...) and the SPATEC appointment events today announce...stry portals SpaTrade (, http://www.SpaTrade.com ...
(Date:8/20/2008)... Survey Report Is Available at http://ww...Newswire/ -- A new survey released today,documents...re leveraging,health information technology (HIT) ...The survey results highlight the need for many HIT...dization and,interoperability to optimize clinical...
(Date:8/20/2008)...use postponed reproductive onset in teen, adult fe...EDNESDAY, Aug. 20 (HealthDay News) -- Alcoholism i...ccording to a study that compared women,s and men,... age when they had their first child. , The re...ian twins born between 1893-1964 (3,634 female and...
Breaking Medicine News(10 mins):Health News:Cytiva's one45 Software Rebrands Healthcare Education Administration Products 2Health News:Cytiva's one45 Software Rebrands Healthcare Education Administration Products 3Health News:Cytiva's one45 Software Rebrands Healthcare Education Administration Products 4Health News:Questex Acquires Leading Spa Industry Portal and Spa Executive Business Networking Site and Events 2Health News:Questex Acquires Leading Spa Industry Portal and Spa Executive Business Networking Site and Events 3Health News:New Health IT Survey for Care Management Services Shows Opportunities for Integration, Standardization and Innovation 2Health News:New Health IT Survey for Care Management Services Shows Opportunities for Integration, Standardization and Innovation 3Health News:Women's Alcohol Use Tied to Delayed Childbearing 2
...hould have enough Calcium in their diet, or may ri...a recent study. // The study was conducted in rat ...s from Tohoku University in Japan to find out whet...ss, the bone surrounding the roots of teeth. They ...
... (EBM) is acclaimed as the "gold-standard" amongst...nd, EBM has shown //support and on the other, has ...ractices, during the least interaction phase with ...tices. Majority of CAM practices are difficult, an...
... cause of end-stage kidney disease worldwide, an i...ents or a kidney transplant for survival. // A res...al Center and the University of Heidelberg has pro...h diabetes from developing severe kidney failure o...
...k are facing one of the worst gastroenteritis epid...f gear, with patients coming// in droves for relie...stomach cramps, which can continue for a few days ...ealth-care centers offering facilities in the grea...
Other Medicine News:Health News:Breastfeeding Mothers Need Calcium to Guard Against Periodontal Diseases 2Health News:Is Evidence-based Medicine Enough to Support Additional Research in Alternative Medicine? 2Health News:A Gene Associated With Severe Kidney Failure in Diabetes Found 2
3D Cranial is the most widely used surgical navigation software. Navigate with confidence and ease with displayed Zone of Accuracy and several fully automated features. 3D Cranial offers seamless int
The D185 is the only stimulator with FDA clearance for this application. The D185 allows transcranial motor evoked potentials to be used in surgical procedures such as scoliosis correction, spinal tu
Designed for the effective positioning of patients during spinal surgery, the frame gives the surgeon a remarkably simple and versatile surgical tool.
The Wilson Plus Radiolucent Wilson Frame delivers unrestricted radiolucency and C-arm integration with a convenient and stable method of maintaining patients in a flexed position for laminectomy, dec
Medicine Products: